ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1363

Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome

Micaela Ana Cosatti1, Silvia Reina2, Cecilia N. Pisoni3, Alicia Eimon4, Sabrina Ganzinelli2 and Enri Borda2, 1Section Rheumatology and Immunology, CEMIC, CABA, Argentina, 2Pharmacology Unit, School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina; National Research Council of Argentina (CONICET), Buenos Aires, Argentina, 3Lupus Research Unit, The Rayne Institute, St Thomas' Hospital and Kings College London, London, United Kingdom, 4CEMIC, Buenos Aires, Argentina

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, cyclooxygenase and prostaglandins, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Innate Immunity and Rheumatic Disease Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: to assess the inflammatory process provoked by the M3 muscarinic acetylcholine receptor antibody from primary Sjogren Syndrome (pSS) patient’s sera in rat submandibular gland by measuring the expression of mRNA COX-2 and production of PGE2 and PGI2.

Methods:

The levels and the generation of PGE2, 6-keto-PGF1α by Enzyme-linked immunoabsorbent assay (ELISA), cyclic AMP (cAMP) by cAMPc-RIA kit and COX-2 mRNA gene’s expression at Real Time PCR in rat submandibular gland acini’s preparations were measured in the presence of the autoantibodies alone or after incubation with different inhibitors. PGE2 and 6-keto-PGF1α were also measured in serum from pSS patients.

Statistical analyses

The Student’s “t” test for unpaired values was used to determine the level of significance. Differences between means were considered significant if P<0.05.

Results:

To determine the effect of pSS IgG anti M3 peptide on gland acini’s we analyzed the time-course of COX-2 mRNA expression by Real Time-PCR. COX-2-mRNA was significantly (P<0.001) increased in the presence of pSS IgG anti M3 versus normal serum (control). When the autoantibody was incubated in the presence of DuP697 (1×10-6 M) [a specific COX-2 antagonist] under the same experimental conditions, it abrogated the increment of COX-mRNA’s expression in a significant manner (P<0.01).

Primary Sjogren Syndrome IgG anti M3 antibody increased the production of both prostanoids PGE2 and 6-keto-PGF1α on submandibular gland acini’s in a dose-response concentration curve reaching the maximal when the antibody concentration is 1×10-8 M. The increment in the generation of both prostanoids is abrogated, reaching values similar to basal ones, when the tissue preparations are incubated with prostanoid antagonists PF-04418948 2×10-9 M  and RO3244794 5×10-8 M  for PGE2 and 6-keto-PGF1α respectively, and in the presence of synthetic M3 peptide 5×10-6 M.

To ascertain if cAMP increment is caused by the generation of PGE2 and 6-keto-PGF1α in our preparation, we studied the action of both prostanoids on the production of this nucleotide. Both prostaglandins were able to increase cAMP production, whereas the selective prostanoids antagonists   (PF-04418948 for PGE2 and RO3244794 for 6-keto-PGF1α) blunted the stimulatory action provoked by the prostaglandins.

The levels of PGE2 and 6-keto-PGF1α were studied in serum of 28 pSS patients and in 25 healthy individuals.  The concentration of 6-keto-PGF1α and PGE2 in serum of pSS patients was two standard deviations higher than that in normal individuals (P<0.001).

Conclusion: The present study suggests a complex interplay between different factors involved in adaptativa autoimmunity in pSS patients at the level of exocrine glands. The presence of anti M3 IgG autoantibody from pSS sera was able to stimulate COX-2 mRNA gene’s expression and the increment in the generation of PGE2 and 6-keto-PGF1α abolished by M3 specific cholinergic antagonist. The prostanoids play an important role in the inflammatory process at exocrine gland level.


Disclosure: M. A. Cosatti, None; S. Reina, None; C. N. Pisoni, None; A. Eimon, None; S. Ganzinelli, None; E. Borda, None.

To cite this abstract in AMA style:

Cosatti MA, Reina S, Pisoni CN, Eimon A, Ganzinelli S, Borda E. Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/changes-in-cyclooxygenase-2s-expression-and-pge2s-and-6-keto-pgf1-levels-in-the-presence-of-the-muscarinic-acethylcholine-receptor-antibody-in-primary-sjogren-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-cyclooxygenase-2s-expression-and-pge2s-and-6-keto-pgf1-levels-in-the-presence-of-the-muscarinic-acethylcholine-receptor-antibody-in-primary-sjogren-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology